Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)
October 25, 2022 11:15 AM EDT
R&D

No­var­tis toss­es more US PD-1 sub­mis­sion plans and an­oth­er an­ti-CD40 drug in­di­ca­tion

Lei Lei Wu

News Reporter

Buried in No­var­tis’ third quar­ter re­port were a few key in­di­ca­tion drops.

First, No­var­tis is no longer plan­ning to sub­mit tislelizum­ab for FDA ap­proval in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

FDA in­spec­tors dis­cov­er trucks car­ry­ing torn-up records leav­ing In­di­an gener­ics fac­to­ry

Ex­clu­sive: Flag­ship-backed Va­lo Health los­es in­ter­im CEO ahead of key Phase 2 read­out

Edge­wise’s stock surges as heart drug pass­es ear­ly safe­ty test

Lasker Award goes to three sci­en­tists who pi­o­neered re­search be­hind GLP-1 drugs

Stem cell start­up spun out of George Church’s lab rais­es $75M

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times